

Press Release

15 February 2023 17:30:00 CET

Invitation to 2cureX webcast on Year-End Report and latest news on February 23, 2023

2cureX will publish its Year-End/Q4 2022 report on Thursday, February 23, at 08:30 CET.

Fernando Andreu (CEO), Ole Thastrup (CSO) and Kenneth G. Johansen (CFO) will host a webcast on Friday, February 24, at 13:00 CET presenting the results and activities of the fourth quarter of 2022 and of the first two months of 2023.

There will be a Q&A session at the end of the presentation.

We look forward to the interaction with shareholders and other investors.

Access the live event at 13:00 CET on Friday, February 24 [here](#).

Best regards
2cureX

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-15 17:30 CET.

Attachments

[Invitation to 2cureX webcast on Year-End Report and latest news on February 23, 2023](#)